Kawai, Akira http://orcid.org/0000-0003-2116-586X
Naka, Norifumi
Shimomura, Akihiko
Takahashi, Shunji
Kitano, Shigehisa
Imura, Yoshinori
Yonemori, Kan
Nakatani, Fumihiko
Iwata, Shintaro
Kobayashi, Eisuke
Outani, Hidetatsu
Tamiya, Hironari
Naito, Yoichi
Yamamoto, Noboru
Doi, Toshihiko
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 4 January 2021
Accepted: 22 March 2021
First Online: 12 June 2021
Declarations
:
: NN, YI, FN, SI, EK, HO, and HT have nothing to declare.AK reports grants and personal fees from Taiho during the conduct of the study; and grants and personal fees from Eisai, Novartis, Takara, Otsuka, and Eli Lilly outside the submitted work.AS reports grants from Taiho during the conduct of the study; grants and personal fees from AstraZeneca and Chugai; and personal fees from Pfizer, Eli Lilly, Eisai, Mundipharma, Daiichi-Sankyo, and Novartis outside the submitted work.ST reports grants and personal fees from Taiho during the conduct of the study; and grants and personal fees from Eisai, Novartis, Chugai, Bayer, AstraZeneca, and MSD outside the submitted work.SK reports grants and personal fees from Boehringer Ingelheim, Eisai, Ono, and REGENERON; personal fees from AstraZeneca, Chugai, Pfizer, Sanofi, Nippon Kayaku, Meiji Seika Pharma, Taiho, Novartis, Daiichi-Sankyo, MSD, Kyowa Hakko Kirin, Celgene, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, AYUMI Pharmaceutical Corporation, Rakuten Medical, PMDA (Pharmaceuticals and Medical Devices Agency), and GSK; and grants from Astellas, Gilead Sciences, AMED (Japan Agency for Medical Research and Development), and JSPS (Japan Society for the Promotion of Science) outside the submitted work.KY reports personal fees from Taiho, Pfizer, AstraZeneca, Eisai, Novartis, Ono, and Chugai outside the submitted work.YN reports speaker’s bureau fees from Pfizer, Taiho, Nippon Kayaku, Eli Lilly, AstraZeneca, Merck Serono, Bayer, Meiji Seika Pharma, Roche Diagnostics, Novartis, Chugai, and Eisai outside the submitted work.NY reports grants and personal fees from Ono, Chugai, Pfizer, Eli Lilly, BMS, Eisai, Takeda, and Boehringer Ingelheim; grants from Taiho, Quintiles, Astellas, BMS, Novartis, Daiichi-Sankyo, Kyowa-Hakko Kirin, Bayer, Janssen Pharma, MSD, Merck, and GSK; and personal fees from AstraZeneca, Otsuka, Cimic, and Sysmex outside the submitted work.TD reports grants and personal fees from Lilly, Kyowa Hakko Kirin, MSD, Daiichi-Sankyo, Sumitomo Dainippon, Taiho, Novartis, Boehringer Ingelheim, Chugai, Bristol-Myers Squibb, and Abbvie; grants from Merck Serono, Janssen, Pfizer, Quintiles, and Eisai; and personal fees from Amgen, Takeda, Bayer, Rakuten Medical, Ono, Astellas Pharma, and Oncolys BioPharma outside the submitted work.
: The study protocol was approved by the institutional review board at each participating site and was conducted per the ethical principles of the Declaration of Helsinki, Pharmaceutical Affairs Law, and Good Clinical Practice.
: All patients provided written informed consent prior to their inclusion in the study.
: The authors have no collaborators to declare.